Literature DB >> 6413939

[Pseudomonas aeruginosa: acquired in vitro resistance to beta-lactams].

A Thabaut, M Meyran.   

Abstract

The development of resistance acquired in vitro to 5 semi-synthetic penicillins: carbenicillin, ticarcillin, azlocillin, mezlocillin, piperacillin and to 5 cephalosporins: cefotaxime, cefoperazone, moxalactam, cefsulodin and ceftazidime, was compared in 6 strains of Pseudomonas aeruginosa. The strains were selected on the basis of their phenotypic resistance: 3 were susceptible to all the betalactam antibiotics tested, 1 was resistant to carbenicillin and ticarcillin but remained susceptible to the others, 2 were susceptible to cefsulodin and ceftazidime but resistant to the others. The development of resistance was investigated by subsequent passages in liquid medium: up to 15 passages or up to an MIC of 4 096 mg/l for a penicillin or 512 mg/l for the cephalosporins. Irrespectively of the phenotypic resistance, for all cephalosorins the MIC became greater than or equal to 64 mg/l and very often greater than or equal to 512 mg/l after 1 to 3 passages. For the penicillin susceptible strains very high MICs were obtained more rapidly with azlocillin and piperacillin (1-2 passages) than with carbenicillin or ticarcillin (5-9 passages). These results are not in favour of a monotherapy with betalactam antibiotics, especially cephalosporins, in the treatment of Pseudomonas aeruginosa infections, but suggest the preferential use of carbenicillin and especially ticarcillin for sensitive isolates.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6413939

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  2 in total

1.  Resistant strains of Pseudomonas aeruginosa isolated after exposure to several beta-lactam antibiotics.

Authors:  J L Hoekstra; A J de Neeling; V van Klingeren; E E Stobberingh; C P van Boven
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

2.  Moxalactam in nosocomial infections with Serratia marcescens.

Authors:  T Mall; F Follath; M Salfinger; R Ritz; H Reber
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.